1
|
Melchor-López A, Suárez-Cuenca JA, Banderas-Lares DZ, De la Peña-Sosa G, Salamanca-García M, Vera-Gómez E, Hernández-Patricio A, Gutiérrez-Buendía JA, Zamora-Alemán CR, Alcaráz-Estrada SL, Ortiz-Fernández M, Montoya-Ramírez J, Felipe Gaytán-Fuentes O, Escamilla-Tilch M, Pineda-Juárez JA, Antonio Téllez-González M, Rodríguez-Arellano ME, Contreras-Ramos A, Hernández-Muñoz RE, Gutiérrez-Salinas J, García S, Mondragón-Terán P. The metabolic phenotype of the patient influences the reduction in carotid intima-media thickness achieved following metabolic surgery. J Int Med Res 2022; 50:3000605221137475. [DOI: 10.1177/03000605221137475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Objectives To determine whether metabolic phenotype is associated with the change in carotid intima-media thickness (CIMT) in patients undergoing bariatric /metabolic surgery (BMS). Methods We performed a case-control study of BMS candidates who had metabolically unhealthy obesity (MUO) or metabolically healthy obesity (MHO). We measured the change in CIMT during the 9 months following BMS. The plasma tumor necrosis factor-α, interleukin-1β, adiponectin, leptin, nitric oxide (NO), vascular endothelial growth factor A (VEGF-A), and malondialdehyde concentrations were determined, adipocyte area was measured histologically, and adipose tissue area was estimated using computed tomography. Results Fifty-six patients (mean age 44.5 years, mean body mass index 44.9 kg/m2, 53% women, and 53% had MUO) were studied. Nine months following BMS, the MUO phenotype was not associated with a significant reduction in CIMT, and that of the MHO group was larger. In addition, fewer participants achieved a 10% reduction in CIMT in the MUO group. A CIMT reduction was associated with lower VEGF-A and NO in the MUO group, while that in the MHO group was associated with a higher NO concentration. Conclusion The metabolic phenotype of patients may influence their change in CIMT following BMS, probably through circulating vasodilatory and pro-inflammatory molecules.
Collapse
Affiliation(s)
- Alberto Melchor-López
- Internal Medicine Department, Hospital General “Xoco” SS CDMX, Mexico City, Mexico
- Internal Medicine Department, Instituto Mexicano del Seguro Social, H.G.Z. No. 8 “Gilberto Flores Izquierdo”, and H.G.Z. No. 58 “Manuel Ávila Camacho”, Mexico City, Mexico
| | - Juan Antonio Suárez-Cuenca
- Internal Medicine Department, Hospital General “Xoco” SS CDMX, Mexico City, Mexico
- Internal Medicine Department, Instituto Mexicano del Seguro Social, H.G.Z. No. 8 “Gilberto Flores Izquierdo”, and H.G.Z. No. 58 “Manuel Ávila Camacho”, Mexico City, Mexico
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | - Diana Zaineff Banderas-Lares
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | - Gustavo De la Peña-Sosa
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | | | - Eduardo Vera-Gómez
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | - Alejandro Hernández-Patricio
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | - Juan Ariel Gutiérrez-Buendía
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | - Carlos Ramiro Zamora-Alemán
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | | | - Moisés Ortiz-Fernández
- Bariatric Surgery Department, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - Jesús Montoya-Ramírez
- Bariatric Surgery Department, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | | | - Mónica Escamilla-Tilch
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - Juan Antonio Pineda-Juárez
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - Mario Antonio Téllez-González
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | | | - Alejandra Contreras-Ramos
- Laboratorio de Biología del Desarrollo y Teratogénesis Experimental, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
| | - Rolando Efraín Hernández-Muñoz
- Departamento de Biología Celular y Desarrollo, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), Coyoacán, Mexico City, Mexico
| | | | - Silvia García
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City. Mexico
| | - Paul Mondragón-Terán
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| |
Collapse
|
2
|
Melchor-López A, Suárez-Cuenca JA, Banderas-Lares DZ, Peña-Sosa GDL, Salamanca-García M, Vera-Gómez E, Hernández-Patricio A, Gutiérrez-Buendía JA, Zamora-Alemán CR, Alcaráz-Estrada SL, Ortiz-Fernández M, Montoya-Ramírez J, Gaytán-Fuentes OF, Pérez-Cabeza de Vaca R, Escamilla-Tilch M, Pineda-Juárez JA, Téllez-González MA, Mondragón-Terán P, Rodríguez-Arellano ME, Contreras-Ramos A, García S, Hernández-Muñoz RE. Identification of adipose tissue-related predictors of the reduction in cardiovascular risk induced by metabolic surgery. J Int Med Res 2021; 49:3000605211012569. [PMID: 34024182 PMCID: PMC8150427 DOI: 10.1177/03000605211012569] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Objectives We aimed to determine whether parameters associated with adipose tissue (adipocyte density and the circulating concentrations of markers of adipose tissue pathology) predict cardiovascular risk (CVR) modification after metabolic surgery (MS). Methods We performed a case–control study of patients with morbid obesity who were candidates for MS. CVR was defined using flow-mediated dilation (FMD) and carotid intima media thickness (CIMT), which were measured during the 9 months following MS. Subgroups of CVR reduction were defined using the following cut-offs: CIMT 10% and/or a two-fold increase in FMD. Results We studied 40 patients with morbid obesity (mean age 44.5 years, 75% women, mean body mass index 46.4 kg/m2) and high prevalences of the metabolically unhealthy obesity phenotype, hypertension, and diabetes mellitus. A significant reduction in CVR was associated with lower vascular endothelial growth factor-A concentration (6.20 vs. 1.59 pg/mL, respectively), low adipocyte density in visceral adipose tissue (100 vs. 80 cells/field), low infiltration with CD68+ cells (18 vs. 8 cells/field) and higher concentrations of lipid peroxidation markers and malondialdehyde (313.7 vs. 405.7 ng/mL). Conclusion The characteristics of adipose tissue and the circulating concentrations of markers of adipose pathology might represent useful predictors of the reduction in CVR following MS. Clinical trial registration number: NCT0356198 (https://clinicaltrials.gov)
Collapse
Affiliation(s)
- Alberto Melchor-López
- Internal Medicine Department, Hospital General "Xoco" SS CDMX, Mexico City, Mexico.,Internal Medicine Department, Instituto Mexicano del Seguro Social, H.G.Z. No. 8 "Gilberto Flores Izquierdo", and H.G.Z. "Troncoso", Mexico City, Mexico
| | - Juan Antonio Suárez-Cuenca
- Internal Medicine Department, Hospital General "Xoco" SS CDMX, Mexico City, Mexico.,Internal Medicine Department, Instituto Mexicano del Seguro Social, H.G.Z. No. 8 "Gilberto Flores Izquierdo", and H.G.Z. "Troncoso", Mexico City, Mexico.,Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Diana Zaineff Banderas-Lares
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Gustavo De la Peña-Sosa
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | | | - Eduardo Vera-Gómez
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Alejandro Hernández-Patricio
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Juan Ariel Gutiérrez-Buendía
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Carlos Ramiro Zamora-Alemán
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | | | - Moisés Ortiz-Fernández
- Bariatric Surgery Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Jesús Montoya-Ramírez
- Bariatric Surgery Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | | | - Rebeca Pérez-Cabeza de Vaca
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Mónica Escamilla-Tilch
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Juan Antonio Pineda-Juárez
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Mario Antonio Téllez-González
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Paul Mondragón-Terán
- Tissue Engineering & Regenerative Medicine Research Group, Coordinación de Investigación, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | | | - Alejandra Contreras-Ramos
- Laboratorio de Biología del Desarrollo y Teratogénesis Experimental, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
| | - Silvia García
- Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico
| | - Rolando Efraín Hernández-Muñoz
- Departamento de Biología Celular y Desarrollo, Instituto de Fisiología Celular; Universidad Nacional Autónoma de México (UNAM), Coyoacán, Mexico City, Mexico
| |
Collapse
|
3
|
Maldonado-Arriaga B, Sandoval-Jiménez S, Rodríguez-Silverio J, Lizeth Alcaráz-Estrada S, Cortés-Espinosa T, Pérez-Cabeza de Vaca R, Licona-Cassani C, Gámez-Valdez JS, Shaw J, Mondragón-Terán P, Hernández-Cortez C, Suárez-Cuenca JA, Castro-Escarpulli G. Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis. Microbiologyopen 2021; 10:e1181. [PMID: 33970546 PMCID: PMC8087925 DOI: 10.1002/mbo3.1181] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 02/27/2021] [Accepted: 03/03/2021] [Indexed: 12/22/2022] Open
Abstract
Ulcerative colitis (UC) is a frequent type of inflammatory bowel disease, characterized by periods of remission and exacerbation. Gut dysbiosis may influence pathophysiology and clinical response in UC. The purpose of this study was to evaluate whether gut microbiota is related to the active and remission phases of pancolitis in patients with UC as well as in healthy participants. Fecal samples were obtained from 18 patients with UC and clinical‐endoscopic evidenced pancolitis (active phase n = 9 and remission phase n = 9), as well as 15 healthy participants. After fecal DNA extraction, the 16S rRNA gene was amplified and sequenced (Illumina MiSeq), operational taxonomic units were analyzed with the QIIME software. Gut microbiota composition revealed a higher abundance of the phyla Proteobacteria and Fusobacteria in active pancolitis, as compared with remission and healthy participants. Likewise, a marked abundance of the genus Bilophila and Fusobacteria were present in active pancolitis, whereas a higher abundance of Faecalibacterium characterized both remission and healthy participants. LEfSe analysis showed that the genus Roseburia and Faecalibacterium were enriched in remission pancolitis, and genera Bilophila and Fusobacterium were enriched in active pancolitis. The relative abundance of Fecalibacterium and Roseburia showed a higher correlation with fecal calprotectin, while Bilophila and Fusobacterium showed AUCs (area under the curve) of 0.917 and 0.988 for active vs. remission pancolitis. The results of our study highlight the relation of gut dysbiosis with clinically relevant phases of pancolitis in patients with UC. Particularly, Fecalibacterium, Roseburia, Bilophila, and Fusobacterium were identified as genera highly related to the different clinical phases of pancolitis.
Collapse
Affiliation(s)
- Brenda Maldonado-Arriaga
- Laboratorio de Metabolismo Experimental e Investigación Clínica, División de Investigación Clínica, C.M.N. "20 de Noviembre", ISSSTE and Hospital General de 2A Troncoso, Instituto Mexicano del Seguro Social, Ciudad de México, México.,Laboratorio de Investigación Clínica y Ambiental, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México
| | - Sergio Sandoval-Jiménez
- Laboratorio de Metabolismo Experimental e Investigación Clínica, División de Investigación Clínica, C.M.N. "20 de Noviembre", ISSSTE and Hospital General de 2A Troncoso, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | - Tomás Cortés-Espinosa
- Clínica de Enfermedad Inflamatoria Intestinal, Servicio de Gastroenterología, C.M.N. "20 de Noviembre", ISSSTE, Ciudad de México, México
| | - Rebeca Pérez-Cabeza de Vaca
- Coordinación de Investigación y División de Investigación Biomédica, C.M.N. "20 de Noviembre", ISSSTE, Ciudad de México, México
| | - Cuauhtémoc Licona-Cassani
- Laboratorio de Genómica Industrial, Centro de Biotecnología FEMSA, Tecnológico de Monterrey, Monterrey, NL, Mexico
| | - July Stephany Gámez-Valdez
- Laboratorio de Genómica Industrial, Centro de Biotecnología FEMSA, Tecnológico de Monterrey, Monterrey, NL, Mexico
| | - Jonathan Shaw
- Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK
| | - Paul Mondragón-Terán
- Coordinación de Investigación y División de Investigación Biomédica, C.M.N. "20 de Noviembre", ISSSTE, Ciudad de México, México
| | - Cecilia Hernández-Cortez
- Laboratorio de Bioquímica Microbiana, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México
| | - Juan Antonio Suárez-Cuenca
- Laboratorio de Metabolismo Experimental e Investigación Clínica, División de Investigación Clínica, C.M.N. "20 de Noviembre", ISSSTE and Hospital General de 2A Troncoso, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Graciela Castro-Escarpulli
- Laboratorio de Investigación Clínica y Ambiental, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México
| |
Collapse
|
4
|
Suárez-Cuenca JA, De La Peña-Sosa G, De La Vega-Moreno K, Banderas-Lares DZ, Salamanca-García M, Martínez-Hernández JE, Vera-Gómez E, Hernández-Patricio A, Zamora-Alemán CR, Domínguez-Pérez GA, Ruíz-Hernández AS, Gutiérrez-Buendía JA, Melchor-López A, Ortíz-Fernández M, Montoya-Ramírez J, Gaytán-Fuentes OF, Toríz-Ortíz A, Osorio-Valero M, Orozco-Vázquez J, Alcaráz-Estrada SL, Rodríguez-Arellano ME, Maldonado-Arriaga B, Pérez-Cabeza de Vaca R, Escamilla-Tilch M, Pineda-Juárez JA, Téllez-González MA, García S, Mondragón-Terán P. Enlarged adipocytes from subcutaneous vs. visceral adipose tissue differentially contribute to metabolic dysfunction and atherogenic risk of patients with obesity. Sci Rep 2021; 11:1831. [PMID: 33469087 PMCID: PMC7815822 DOI: 10.1038/s41598-021-81289-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Accepted: 12/30/2020] [Indexed: 12/20/2022] Open
Abstract
Morphological characteristics and source of adipose tissue as well as adipokines may increase cardiometabolic risk. This study aimed to explore whether adipose tissue characteristics may impact metabolic and atherogenic risks. Subcutaneous Adipose Tissue (SAT), Visceral Adipose Tissue (VAT) and peripheral blood were obtained from obese patients submitted to bariatric surgery. Adipose tissue (morphometry), plasma adiponectin, TNF-α, resistin (multiplexing) and biochemical chemistry were analyzed; as well as endothelial dysfunction (Flow Mediated Dilation, FMD) and atherogenesis (Carotid Intima Media Thickness, CIMT). Subgroups divided by adipocyte size and source were compared; as well as correlation and multivariate analysis. Sixty patients 36.6% males, aged 44 years-old, BMI 46.7 kg/m2 were included. SAT's adipocytes showed a lower range of size expandability than VAT's adipocytes. Independent from their source, larger adipocytes were associated with higher glucose, lower adiponectin and higher CIMT. Particularly, larger adipocytes from SAT were associated with higher blood pressure, lower insulin and HDL-cholesterol; and showed positive correlation with glucose, HbA1c, systolic/diastolic values, and negatively correlated with insulin and adiponectin. VAT's larger adipocytes particularly associated with lower resistin and lower FMD values. Gender and Diabetes Mellitus significantly impacted the relation of adipocyte size/source with the metabolic and atherogenic risk. Multivariable analysis suggested hypertension-resistin-HbA1c interactions associated with SAT's larger adipocytes; whereas potential insulin-adiponectin associations were observed for VAT's larger adipocytes. Adipocyte morphology and source are differentially related with cardiometabolic and atherogenic risk in population with obesity, which are potentially affected by gender and Diabetes Mellitus.
Collapse
Affiliation(s)
- Juan Antonio Suárez-Cuenca
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico.
- Internal Medicine Department, H.G.Z. No. 58 "Manuel Ávila Camacho", IMSS, and Hospital General "Xoco" SS CDMX, 03340, Mexico City, Mexico.
| | - Gustavo De La Peña-Sosa
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Karen De La Vega-Moreno
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Diana Zaineff Banderas-Lares
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Moisés Salamanca-García
- Pathology Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03104, Mexico City, Mexico
| | - José Enrique Martínez-Hernández
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Eduardo Vera-Gómez
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Alejandro Hernández-Patricio
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Carlos Ramiro Zamora-Alemán
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Gabriela Alexandra Domínguez-Pérez
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Atzín Suá Ruíz-Hernández
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Juan Ariel Gutiérrez-Buendía
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Alberto Melchor-López
- Internal Medicine Department, H.G.Z. No. 8 "Gilberto Flores Izquierdo", IMSS and Hospital General "Xoco" SS CDMX, 03340, Mexico City, Mexico
| | - Moisés Ortíz-Fernández
- Bariatric Surgery Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Jesús Montoya-Ramírez
- Bariatric Surgery Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Omar Felipe Gaytán-Fuentes
- Bariatric Surgery Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Angélica Toríz-Ortíz
- Diagnostic Imaging Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Mario Osorio-Valero
- Diagnostic Imaging Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Julita Orozco-Vázquez
- Diagnostic Imaging Department, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | | | | | - Brenda Maldonado-Arriaga
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Rebeca Pérez-Cabeza de Vaca
- Coordination of Research and Tissue Engineering & Regenerative Medicine Research Group, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Mónica Escamilla-Tilch
- Coordination of Research and Tissue Engineering & Regenerative Medicine Research Group, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Juan Antonio Pineda-Juárez
- Coordination of Research and Tissue Engineering & Regenerative Medicine Research Group, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Mario Antonio Téllez-González
- Coordination of Research and Tissue Engineering & Regenerative Medicine Research Group, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| | - Silvia García
- Laboratory of Experimental Metabolism and Clinical Research, Division of Research, Department of Clinical Research, Centro Médico Nacional "20 de Noviembre", ISSSTE, 502, San Lorenzo, Colonia Del Valle, Delegación Benito Juárez, 03100, Mexico City, Mexico
| | - Paul Mondragón-Terán
- Coordination of Research and Tissue Engineering & Regenerative Medicine Research Group, Centro Médico Nacional "20 de Noviembre", ISSSTE, 03100, Mexico City, Mexico
| |
Collapse
|
5
|
Bonilla-Muro MG, Hernández de la Cruz ON, Gonzalez-Barrios JA, Alcaráz-Estrada SL, Castañón-Arreola M. EsxA mainly contributes to the miR-155 overexpression in human monocyte-derived macrophages and potentially affect the immune mechanism of macrophages through miRNA dysregulation. J Microbiol Immunol Infect 2019; 54:185-192. [PMID: 31561988 DOI: 10.1016/j.jmii.2019.07.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 03/24/2019] [Accepted: 07/19/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND/PURPOSE Mycobacterium tuberculosis is a successful intracellular pathogen that uses multiple proteins to survive within macrophages, one of the most remarkable is the virulence factor EsxA. In this study, we evaluate the participation of EsxA in the miRNAs expression profile of human monocyte-derived macrophages (hMDM), to mapping out the contribution of this virulence factor in the miRNA profile and how these changes can influence and alter immune-related processes and pathways. METHODS The cytotoxic effect of rEsxA on hMDM was evaluated by the neutral red assay. The evaluation of miRNA expression profile in infected and rEsxA-stimulated hMDM was done using TaqMan Low Density Assays, and in silico analyses was carried on to construct Protein-Protein Interaction network of miRNAs targets. RESULTS miR-155 was the only miRNA upregulated consistently in hMDM infected with M. tuberculosis H37Rv or stimulated with rEsxA. In hMDM stimulated with rEsxA, we found 25 miRNA's dysregulated (8 up-regulated and 17 down-regulated). The most significant were the miR-155 and miR-622 that has been observed in the analysis carried out with two different endogenous controls (U6 snRNA and RNU44) for the normalization of expression analysis. This result suggests that rEsxA induces the deregulation of miRNAs that potentially target genes in key pathways for the infection control, like the MAPK signaling pathway, cytokines, and chemokine signaling pathways, and several connected pathways involved in mycobacterial uptake, vesicular traffic, and endosome maturation. CONCLUSION Higher expression levels of miR-155 suggest potential roles of these miRNA in EsxA-dependent immune subversion.
Collapse
Affiliation(s)
| | | | - Juan Antonio Gonzalez-Barrios
- Coordinación de Capacitación, Desarrollo e Investigación, Hospital Regional 1º de Octubre, ISSSTE, Mexico City, Mexico
| | | | | |
Collapse
|